PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2447/10/11 Eli Lilly

Anonymous v Lilly (AUTH/2447/10/11): Alleged promotion of Cialis – no case report (outwith scope)

Complaint about alleged promotion of Cialis. PMCPA recorded no breach because the matter was outwith the scope of the Code; no case…

2018
CASE
AUTH/3057/8/18 Novo Nordisk ⭐ Case of the Week

AUTH/3057/8/18: CCG employee v Novo Nordisk (Victoza) β€” no breach over alleged handwritten eGFR claim

CCG alleged a Novo Nordisk rep asked a receptionist to add a handwritten Victoza claim about use at eGFR <15. Panel found…

2019
CASE
AUTH/3149/1/19 Endo Ventures

Endo Ventures breached ABPI Code over fluoxetine ad claim β€œfor treatment of depressive illness” (AUTH/3149/1/19)

A Pulse ad for fluoxetine used the broad claim β€œfor treatment of depressive illness”. PMCPA ruled it didn’t accurately reflect the SPC…

2019
CASE
AUTH/3224/7/19 Vifor Pharma

AUTH/3224/7/19: Vifor misleading comparative safety claims for Ferinject vs Monofer and misused β€œmedical information” response

Vifor’s reps used materials implying Ferinject had fewer ADRs than Monofer. A follow-up β€œmedical information” email was ruled promotional, misleading and disparaging.…

2019
CASE
AUTH/3276/10/19 Ipsen

Ipsen: Global LinkedIn post linking to ENGAGE press release ruled public promotion of Dysport (AUTH/3276/10/19)

A global Ipsen LinkedIn post featuring a UK-based employee quote linked to an ENGAGE study press release. PMCPA said this brought the…

2019
CASE
AUTH/3213/6/19 Janssen

AUTH/3213/6/19: Anonymous v Janssen β€” alleged off-licence promotion at prostate cancer summit (No breach)

Anonymous complaint alleged off-licence, misleading and disguised promotion at a Janssen-sponsored oncology meeting. Panel ruled no breach as allegations lacked specificity and…

2020
CASE
AUTH/3367/7/20 GlaxoSmithKline ⭐ Case of the Week

GSK Duac banner ad on Pulse Today: complaint about missing prescribing information (AUTH/3367/7/20) – No breach

A UK health professional said a Duac 5% Pulse Today banner was static and lacked prescribing info. GSK said it was a…

2019
CASE
AUTH/3188/4/19 Bayer

Anonymous v Bayer (AUTH/3188/4/19): Third-party email linked Xarelto to sponsored anticoagulation therapy review service

Complaint about a third-party provider’s internal email linking Bayer’s AF therapy review service to Xarelto. Panel found breach of Clause 9.1 (high…

2020
CASE
AUTH/3299/1/20 Novo Nordisk

Novo Nordisk breached ABPI Code over Saxenda materials at fertility conference lacking prominent pregnancy warnings (AUTH/3299/1/20)

At a fertility conference, Saxenda materials and patient brochure lacked clear, prominent pregnancy/trying-to-conceive warnings. Appeal Board found misleading safety presentation, inadequate rep…

2020
CASE
AUTH/3370/8/20 Ferring Pharmaceuticals

Ferring: Uncertified Nocdurna supplement remained accessible online years after intended withdrawal (AUTH/3370/8/20)

A Ferring-sponsored nocturia supplement with UK Nocdurna prescribing info stayed accessible online for 2.5+ years beyond its Dec 2017 end date and…

2020
CASE
AUTH/3398/10/20 Merck Sharp & Dohme

MSD voluntary admission: Steglatro formulary guide visible to the public due to transparent journal wrappers (AUTH/3398/10/20)

A Steglatro formulary decision guide intended for HCPs was visible through transparent wrappers used for some mailed journals. MSD admitted a breach…

2019
CASE
Daiichi-Sankyo UK ⭐ Case of the Week

Daiichi-Sankyo: sponsorship disclosure in third-party YouTube meeting recording (Lixiana) found unclear from the outset

A patient complained about a YouTube-hosted meeting recording mentioning Lixiana. Most allegations were not upheld, but Daiichi-Sankyo was found in breach for…

2020
CASE
AUTH/3439/12/20 Amgen

Amgen disease awareness newspaper ad ruled misleading due to β€œflu jab alongside your osteoporosis medicine” wording (AUTH/3439/12/20)

A national newspaper osteoporosis awareness ad β€œsupported by Amgen” was not POM promotion, but was ruled misleading for implying patients could get…

2021
CASE
AUTH/3500/4/21 Sanofi

AUTH/3500/4/21: Employee complaint about representative training at Sanofi (No breach)

Anonymous employee alleged poor diabetes rep training and over-reliance on a fellow representative. Panel found complaint unproven on balance of probabilities; no…

2021
CASE
AUTH/3505/4/21 Britannia

AUTH/3505/4/21: Complainant v Britannia β€” advisory boards and nursing service (No breach)

Anonymous ex-employee alleged Lecigon advisory boards were marketing-led/disguised promotion and that a nursing service was compromised by sales access to patient data.…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training